This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Opdualag (nivolumab and relatlimab)
General Description:
Opdualag is a premixed intravenous (IV) combination of nivolumab and relatlimab used to treat adults with advanced melanoma that has spread or cannot be surgically removed. It is also indicated for children aged 12 years and older with advanced melanoma.
Opdualag works by blocking immune checkpoint proteins to enhance the body’s immune response against cancer cells. Treatment is administered as an IV infusion under the supervision of a qualified healthcare professional, with dosing tailored to patient needs.
Getting Opdualag in India
Opdualag was approved by the FDA in March 2022 and by the EMA in September 2022. While it may not yet be commercially available in India, patients can access it legally through a Named Patient Program (NPP) under the guidance of a licensed physician.
MitoGENE assists Indian patients in obtaining Opdualag safely, managing all regulatory approvals, import permits, and logistics to ensure a secure and compliant process.
Disease Indication:
• Skin Cancer / Advanced Melanoma
Manufacturer:
Bristol-Myers Squibb
Usage:
Intravenous
Medicine Approved By:
• Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
Available Dosage Form & Package:
• Single-dose vial: 240 mg nivolumab + 80 mg relatlimab per 20 mL
Shipping:
Room Temperature Shipping
Opdualag is shipped at controlled room temperature (15–25°C) to maintain stability and effectiveness. Standard shipping procedures ensure the medication remains safe and uncompromised during transit.
How to Access Opdualag (nivolumab and relatlimab) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Opdualag (nivolumab and relatlimab) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
